ABG-WTT Global Life Science Capital Partners GP Ltd
ABG-WTT Global Life Science Capital Partners GP Ltd reported 2 US-listed holdings worth $8.6 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Ceribell Inc. (62.6%) and Rapid Micro Biosystems Class A Ord (37.4%). Against the quarter before, it opened 0 positions, added to 0, trimmed 1 and sold out of 0.
The 2 largest of its 2 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned -43.1% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Trimmed 1
- Ceribell Inc. CBLL-166,492 shares · -38%
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Ceribell Inc. CBLL | 275.3K | $5.4 million | 62.61% | -166.5K |
| Rapid Micro Biosystems Class A Ord RPID | 1.8M | $3.2 million | 37.39% | no change |